Amanda Lanier
Production Editor at BioWorld
Articles
-
2 weeks ago |
bioworld.com | Amanda Lanier
Antylia’s $1.34B deal tops cooling med-tech M&A activity in MayMed-tech M&A activity dipped in May, reaching $1.52 billion, down from $2.07 billion in April and a far cry from the highs seen earlier this year, such as $4.92 billion in January and $5.99 billion in February. BioWorld MedTech Deals and M&A
-
2 weeks ago |
bioworld.com | Amanda Lanier
Index insights Safety scares and trial misses drag down neuro biotechs into Q2 The BioWorld Neurological Diseases Index continued its downward slide into 2025, with 15 of the 20 component stocks posting losses. After dipping into negative territory in late February, the index dropped 15.99% by the end of March and closed May down 22.34%. BioWorld Analysis and data insight Neurology/psychiatric
-
2 weeks ago |
bioworld.com | Amanda Lanier
Biopharma deals May 2025Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activityBiopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That figure marks a nearly 20% increase over the $86.68 billion recorded during the same period in 2024. BioWorld Analysis and data insight Deals and M&A
-
2 weeks ago |
bioworld.com | Amanda Lanier
Home » May med-tech financings surged to $3.51B BioWorld briefs for June 10, 2025. BioWorld MedTech briefs for June 9, 2025. Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company... In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant... Omada Health Inc.
-
2 weeks ago |
bioworld.com | Amanda Lanier
Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma companies raised $5.55 billion in May, more than doubling the $2.4 billion raised in April. May saw two biopharma IPOs totaling $37.5 million. Apimeds Pharmaceuticals US Inc.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →